The USFDA has given approval for fluorouracil injection, a cancer medication, to Alembic Pharma.

0
504
WhatsApp D. Pharma Group Join Now
Telegram D. Pharma Group Join Now
Telegram Group Latest Pharma Jobs Join Now
Telegram B. Pharma Group Join Now
Telegram Medicine Update Group Join Now
WhatsApp B. Pharma/ GPAT Channel Join Now

Alembic Pharmaceuticals Ltd (Alembic) declared that its Abbreviated New Drug Application (ANDA) fluorouracil injection USP, 2.5 g/50 mL (50 mg/mL) pharmacy bulk vial has been given final FDA approval. The reference listed drug product (RLD), Fluorouracil Injection, 2.5 g/50 mL (50 mg/mL), of Spectrum Pharmaceuticals, Inc., is therapeutically equivalent to the ANDA that has been approved (Spectrum). Patients with adenocarcinomas of the breast, colon, rectum, gastric, and pancreatic organs are recommended to receive fluorouracil injection as a treatment.

According to IQVIA, the market for fluorouracil injection USP, 2.5 g/50 mL (50 mg/mL) vial is expected to be worth US$ 5 million for the twelve months ending December 2022. Alembic has received 182 ANDA approvals from the US FDA overall (159 final approvals and 23 tentative clearances).

Since 1907, Alembic Pharmaceuticals Limited has been a leader in pharmaceutical research and development. The company is vertically integrated.

Download Pharmacy India Mobile App from Play store for the preparation of GPAT, NIPER, Pharmacist, DI and other Pharma Exams.

LEAVE A REPLY

Please enter your comment!
Please enter your name here